-transparent.png){kind=logo}
1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non-cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large.
Related Publications
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
October 1990,
British journal of clinical pharmacology,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
January 1991,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
August 1990,
Journal of the National Cancer Institute,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
January 1989,
Psychopharmacology series,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
January 1991,
European journal of clinical pharmacology,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
January 1991,
European journal of cancer (Oxford, England : 1990),
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
November 1992,
Acta psychiatrica Scandinavica,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
July 1989,
Cancer research,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
January 1991,
European journal of clinical pharmacology,
C J Speirs, and
S Murray, and
D S Davies, and
A F Biola Mabadeje, and
A R Boobis
March 1991,
Breast cancer research and treatment,
